Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8716502 | Journal de Mycologie Médicale / Journal of Medical Mycology | 2018 | 6 Pages |
Abstract
All the compounds were able to completely inhibit the yeast growth. β-lapachone and α-nor-lapachone were the less cytotoxic compounds against L929 and RAW 264.7 cells. At IC50, β-lapachone inhibited morphogenesis in 92%, while the treatment of yeast cells with α-nor-lapachone decreased yeast-to-hyphae transition in 42%. At 50 μg/ml, β-lapachone inhibited biofilm formation by 84%, whereas α-nor-lapachone reduced biofilm formation by 64%. The treatment of yeast cells with β-lapachone decreased cell wall mannoproteins availability in 28.5%, while α-nor-lapachone was not able to interfere on this virulence factor. Taken together, data show that β-lapachone and α-nor-lapachone exhibited in vitro cytotoxicity against a fluconazole-resistant C. albicans strain, thus demonstrating to be promising candidates to be used in the treatment of infections caused by this fungus.
Related Topics
Life Sciences
Immunology and Microbiology
Parasitology
Authors
D.C. Moraes, J.A.R. Curvelo, C.A. Anjos, K.C.G. Moura, M.C.F.R. Pinto, M.B. Portela, R.M.A. Soares,